ML188 is a potent and selective non-covalent SARS-CoV 3CLpro inhibitor with an IC50 of 1.5 μM.

Ensitrelvir (also known as S-217622; trade name Xocova) is an orally bioavailable, non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC50=13 nM) effective against the Omicron variant. On Nov 22, 2022, Ensitrelvir gained its first approval in Japan under the emergency regulatory approval system (EUA). It is an antiviral drug developed by Shionogi in partnership with Hokkaido […]

Dihydrotanshinone I is a naturally occuring phenanthrene-quinone found in Salvia miltiorrhiza Bunge that has been widely used for treating cardiovascular diseases.

Cepharanthine is a naturally occurring biscoclaurine alkaloid with antiinflammatory and antiviral (against COVID-19) activity.

Merafloxacin (CI-934; CI934; CI 934), an antibacterial belonging to the fluoroquinolone class, is a novel and potent −1 PRF (programmed -1 ribosomal frameshifting) inhibitor of SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2). It inhibits −1 PRF of SARS-CoV-2, SARS-CoV, as well as that of other beta coronaviruses. Inhibition of −1 PRF by merafloxacin impeded SARS-CoV-2 […]

Carmofur (also known as HCFU), a derivative of fluorouracil (5-FU) which is an antimetabolite class of anticancer drug, is a novel, highly potent acid ceramidase inhibitor used in the treatment of breast and colorectal cancer. Carmofur is one of the masked compounds (a sort of prodrug) of 5-FU, which was modified to achieve more potent […]

XP-59 is a novel and potent inhibitor of the SARS-CoV Mpro

Ensitrelvir fumarate (S-217622 fumarate; Xocova) is a novel and orally bioavailable SARS-CoV-2 3CL protease inhibitor (IC50=13 nM) approval in Japan under the emergency regulatory approval system (EUA) for COVID-19 treatment.